Editors
Silvia Montoto
St Bartholomew's Hospital, Barts Health NHS Trust, London, UK
Silvia Montoto is a haemato-oncologist who trained at the Hospital Clínic de Barcelona in Spain. Since 2004, she has been working in the Haemato-oncology Department at St Bartholomew’s Hospital in London, UK as a consultant haemato-oncologist with a specific interest in lymphoma.
Dr Montoto’s special fields of interest are follicular lymphoma (which was the subject of her MDRes ‘Study of BCL-2 rearrangement and other prognostic factors in follicular lymphoma‘), the management of lymphoma in patients with human immunodeficiency virus (HIV) infection and the role of stem cell transplant and other cell therapies in patients with lymphoma. She is the author of around 200 papers published in peer-reviewed journals and is a regular reviewer for numerous peer-reviewed journals, international meetings and international funding bodies. She has also participated as a speaker in multiple educational programmes at international meetings (the European Society for Medical Oncology [ESMO], the European Hematology Association [EHA], the European Group for Blood and Marrow Transplantation [EBMT] and the American Society of Hematology [ASH]).
Martin Dreyling
Hospital of the Ludwig-Maximilians-University Munich (LMU), Munich, Germany
Martin Dreyling is Professor of Medicine and head of the lymphoma programme in the Department of Medicine III, LMU Hospital, Munich, Germany. He studied at the Universities of Düsseldorf, Giessen, Tübingen and Würzburg, and completed his clinical training at the Universities of Bonn, Münster, Göttingen and Munich, Germany. He was also a visiting scientist at the University of Chicago, Chicago, USA..
Prof. Dreyling’s scientific focus is on the molecular basis of malignant transformation, cell-cycle dysregulation and secondary genetic alterations as well as biological prognostic factors in malignant lymphoma. He is also interested in innovative therapeutic approaches, including molecular targeted approaches such as inhibitors of the B-cell receptor pathway and immunological approaches.
Prof. Dreyling is a coordinator of the European MCL Network and president of the German Lymphoma Alliance as well as a member of the European Hematology Association (EHA) executive board. He has co-authored numerous scientific papers, book chapters and abstracts in international peer-reviewed journals.
Veronika Ballova
Onkologie Kantonsspital, Baden, Switzerland
Dr Veronika Ballova is a senior medical oncologist at the Onkologie Kantonsspital in Baden, Switzerland. She graduated in medicine from the Comenius University Bratislava, Slovakia, and completed her specialist training in clinical oncology at the National Cancer Institute (NCI) in Bratislava, Slovakia.
Dr Ballova worked as an assistant professor in the Department of Microbiology of the University of Bratislava, and as a resident at the NCI in Bratislava, Slovakia. In 2003 she also completed an ESMO fellowship at the University Hospital in Cologne, Germany, with the German Hodgkin Study Group. Since then, her career has been mainly focused on haematological malignancies, working for 20 years as a medical oncologist in the Department of Lymphoproliferative Diseases & Hematologic Malignancies, Bone Marrow Transplantation Unit of the NCI in Bratislava, Slovakia. She serves as a member of the European Society of Medical Oncology (ESMO) Educational Publications Working Group (Deputy Chair: 2022-2023), as a member of Slovak Oncology Society (S.O.S), Slovak Society for Haematology (SHS), and International Extranodal Lymphoma Study Group (IELSG). She also served as chair of the Slovak Lymphoma Group (LySk) from 2012 to 2015.
Dr Ballova is the author of several papers published in peer-reviewed international journals and has been an invited speaker at several national meetings. She has also collaborated on international publications (books), as an author and editor.
Contributors
S Araf
Department of Haemato-oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK
A Arribas
Institute of Oncology Research, Faculty of Biomedical Sciences, USI (Università della Svizzera italiana), Bellinzona; Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland
V Ballova
Department of Oncology and Hematology, Kantonsspital Baden, Baden, Switzerland
Y Benavente
Unit of Molecular and Genetic Epidemiology in Infections and Cancer, Catalan Institute of Oncology (ICO-IDIBELL), L'Hospitalet de Llobregat, Barcelona; Centro de Investigación Biomédica en Red, Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
F Bertoni
Institute of Oncology Research, Faculty of Biomedical Sciences, USI (Università della Svizzera italiana), Bellinzona; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
M Blanco
Puerta de Hierro University Hospital, Madrid, Spain
P Borchmann
First Department of Internal Medicine and German Hodgkin Study Group, University Hospital Cologne, Cologne, Germany
A Borra
Onco-Hematology Department, Centre Antoine Lacassagne, Nice, France
E Campo
Department of Pathology, Hospital Clínic of Barcelona, Barcelona; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona; University of Barcelona, Barcelona, Spain
D Casabonne
Unit of Molecular and Genetic Epidemiology in Infections and Cancer, Catalan Institute of Oncology (ICO-IDIBELL), L'Hospitalet de Llobregat, Barcelona; Centro de Investigación Biomédica en Red, Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
MED Chamuleau
Department of Haematology, Amsterdam University Medical Center, Location VUMC, Amsterdam, Netherlands
A Chiappella
Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
F d’Amore
Department of Hematology, Aarhus University Hospital, Aarhus, Denmark
A Davies
Southampton Experimental Cancer Medicine Centre, Faculty of Medicine, University of Southampton, Southampton, UK
MA Dimopoulos
Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
M Dreyling
Department of Medicine III, University Hospital, Ludwig-Maximilians-University, Munich, Germany
DA Eichenauer
First Department of Internal Medicine and German Hodgkin Study Group, University Hospital Cologne, Cologne, Germany
AJM Ferreri
Lymphoma Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
G Frigola
Department of Pathology, Hospital Clínic of Barcelona, Barcelona; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona; University of Barcelona, Barcelona, Spain
A Gallamini
Research and Clinical Innovation Department, Centre Antoine Lacassagne, Nice, France
M Ghielmini
Medical Oncology Clinic, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
G Hess
Department of Hematology, Oncology and Pneumology & University Cancer Center, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
M Hutchings
Department of Haematology and Phase 1 Unit, Rigshospitalet, and Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
E Kastritis
Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
M Kättström
Division of Hematology, Department of Medicine, Faculty of Medicine and Health, Örebro University, Örebro, Sweden
E Kimby
Division of Hematology, Department of Medicine at Huddinge, Karolinska Institute, Stockholm, Sweden
L Mazzucchelli
Istituto Cantonale di Patologia, Locarno, Switzerland
A Moccia
Medical Oncology Clinic, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
C Montalban
Department of Pathology and Translational Research, Fundación MD Anderson, MD Anderson Cancer Center, Madrid, Spain
S Montoto
Department of Haemato-oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK
A Muntañola
Department of Haematology, Hospital Universitari Mutua de Terrasa (HUMT), Barcelona, Spain
MB Pedersen
Department of Hematology, Aarhus University Hospital, Aarhus, Denmark
L Petrikova
Department of Onco-hematology, Comenius University and National Cancer Institute, Bratislava, Slovakia
M Ponzoni
Ateneo Vita-Salute San Raffaele University and Diagnostic Area of Hematopathology, Pathology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
M Provencio
Puerta de Hierro University Hospital, Madrid, Spain
KD Quint
Department of Dermatology, Leiden University Medical Center, Leiden, Netherlands
C Sarkozy
DITEP, Gustave Roussy, Villejuif, France
D Scott
University Hospital Southampton NHS Foundation Trust, Southampton, UK
D Soldini
Pathologie Zentrum Medica, Zürich, Switzerland
C Thieblemont
Université de Paris; Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Hémato-oncologie, Paris, France
M-K Tilch
Department of Hematology, Oncology and Pneumology & University Cancer Center, University Medical Center of the Johannes Gutenberg University, Mainz, Germany
U Vitolo
Medical Oncology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo (Torino), Italy
T Weiglein
Department of Medicine III, University Hospital, Ludwig-Maximilians-University, Munich, Germany
R Willemze
Department of Dermatology, Leiden University Medical Center, Leiden, Netherlands
E Zucca
Institute of Oncology Research, Faculty of Biomedical Sciences, USI (Università della Svizzera italiana), Bellinzona; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
